What's Happening?
Smith+Nephew has announced that the American Medical Association (AMA) CPT Editorial Panel has established a Category I Current Procedural Terminology (CPT) code for procedures involving its CARTIHEAL AGILI-C Cartilage Repair Implant, effective January 1, 2027. The implant is a single-stage, off-the-shelf solution for treating cartilage and osteochondral defects in the knee, including in patients with mild to moderate osteoarthritis. The new CPT code recognizes the clinical significance and growing adoption of the implant, which demonstrated an 87% reduction in the relative risk of total knee arthroplasty or osteotomy at 4 years compared to microfracture or debridement.
Why It's Important?
The establishment of a new CPT code for the CARTIHEAL Implant is a major milestone for Smith+Nephew, facilitating broader access to the technology and streamlining reimbursement processes for providers and payers. This development validates the clinical value of the implant and supports its integration into standard clinical practice. The implant offers an additional treatment option for patients with knee cartilage defects, addressing a true unmet need in the field of cartilage repair.
What's Next?
The new CPT code will become effective on January 1, 2027, enabling healthcare providers to integrate the CARTIHEAL Implant into standard clinical practice. Smith+Nephew plans to continue promoting the implant's benefits and expanding its adoption among physicians and patients. The company will showcase the implant at the ICRS 2025 in Boston, MA, and continue to support its clinical efficacy and safety.
Beyond the Headlines
The recognition of the CARTIHEAL Implant by the AMA highlights the importance of innovative medical devices in addressing unmet clinical needs. Smith+Nephew's focus on repair, regeneration, and replacement of soft and hard tissue reflects a broader trend in the medical technology industry towards improving patient outcomes through advanced solutions.
